Posted by admin | Posted in Health Care, Pharmacies | Posted on 15-09-2009
World Health Organization WHO (World Health Organization) said that antiviral drugs should not be used to prevent influenza A-H1N1 although most cases of drug resistance was associated with treatment before the infection.
“The risk of resistance appears more common in people taking oseltamivir for prevention purposes after the close and although the infected patients taking oseltamivir,” the UN official explained in a statement.
Oseltamivir is commonly known by the trade name Tamiflu is the drug recommended by WHO to deal with the A-H1N1 flu. The UN says that 12 of 28 cases of Tamiflu resistance is associated with the use intended for the prevention.
Six other cases of resistance occurred in patients with severe immunosuppression and four occurred due to use of Tamiflu for treatment.
Two further cases of resistance were identified in people who do not use Tamiflu as either prevention or treatment, clearly the WHO, which then stated that there was another alternative antiviral drug Relenza product of GlaxoSmithKline.
Overall, the number of cases this resistance are “sporadic and not often”. Generally, the WHO does not recommend the use of antiviral drugs for prevention purposes.
Of course, for those who contracted the flu and those who suffer from certain diseases that complications of high risk of contracting, the choice is to alleviate the existing symptoms, how to take existing drugs that do not develop symptoms become severe, WHO officials said
